| Drug Name: | Losartan (114798-26-4) |
|---|---|
| PubChem ID: | 3961 |
| SMILES: | CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl |
| InchiKey: | PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
| Therapeutic Category: | Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents, Cardiovascular Agents |
| Molecular Weight (dalton) | : | 422.92 |
| LogP | : | 4.2668 |
| Ring Count | : | 4 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 92.51 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Indomethacin (53-86-1) | Attenuate The Antihypertensive Effect Of Losartan | Antagonistic | Prostaglandins are partially involved in the hypotensive action of angiotensin II receptor antagonists, and that NSAIDs, hence by inhibiting prostaglandin synthesis they may antagonise their effects | Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals |
| Mannitol (69-65-8) | Renal Failure | Antagonistic | Not Understood | Mannitol-induced toxicity in a diabetic patient receiving losartan |
| Fluconazole (86386-73-4) | Reduces The Conversion Of Losartan To Its Active Metabolite | Antagonistic | Uncertain | Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Decreased Antihypertensive Effect | Cytochrome P450 2C9 (P11712) | Individuals homozyGOus for Leu359 have markedly diminished metabolic capacities for most CYP2C9 substrates Consistent with the modulation of enzyme activity by genetic and other factors@ wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates Finally@it decreased antihypertensive effect of losartan [ ADR Type 1 ] | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category